Reusable Device Cycle Limits: How to Justify Reprocessing Claims

What Regulators Actually Require for Reuse Life

When regulatory affairs and quality engineering teams finalize the validation master plan and instructions for use (IFU) for a reusable medical device family, one central question recurs: should the labeling state a hard cycle count, an objective end-of-life inspection criterion, or an unspecified service life under routine maintenance? The short, definitive answer is that no global health authority fixes a mandatory maximum number of reprocessing cycles for any medical device category. Neither the United States Food and Drug Administration (FDA) nor Regulation (EU) 2017/745 sets a statutory number of reprocessing cycles for a device category. A figure such as 50 or 100 cycles is the manufacturer's own claim, and it is supportable only when the validation file actually evaluates the device at that state.

Instead of dictating numerical caps, global regulators enforce a rigorous claim-to-evidence framework. If the instructions state a specific cycle count, that statement is a performance claim. FDA's 2015 reprocessing guidance says the labeling should inform the user how many times the device can be reused, based on testing. EU MDR Annex I requires information that identifies when the device should no longer be reused. The file should show that the characteristics you still claim — function, biological safety, cleaning, and the terminal microbicidal process — were addressed at the state the label describes. If the label instead tells the user to stop when the device has exceeded its use life, FDA says the labeling should identify a method to show the device is still within performance specifications, plus instructions for disposing of devices that fail. The guidance examples are a built-in automatic pre-check, a performance test that should be passed before reuse, and visual inspection with failure criteria such as corrosion, discoloration, pitting, or cracked seals. For difficult-to-see areas, especially lumens, the labeling should recommend how to evaluate deterioration, and leak testing is the guidance's example.

Understanding how to structure and defend this decision requires navigating three distinct regulatory tiers:

• Binding European Statutory Law (EU MDR Annex I, GSPR 23.4(n)): Unlike FDA guidance, the General Safety and Performance Requirements of Regulation (EU) 2017/745 apply directly in the European Union. GSPR 23.4(n) requires the instructions for use of a reusable device to give information on the appropriate processes for allowing reuse, including cleaning, disinfection, packaging and, where appropriate, the validated method of re-sterilisation appropriate to the Member State or Member States in which the device has been placed on the market. It also requires 'information to identify when the device should no longer be reused, e.g. signs of material degradation or the maximum number of allowable reuses.' Those two items are examples of the information that identifies when reuse should stop, not a finding that every device may freely pick either route without evidence. A cycle count still has to be the maximum number of allowable reuses you can support. Degradation signs still have to be specific enough for a processor to apply. Choosing one example does not remove the duty to describe the processes that allow reuse.

• U.S. Statutory Premarket Validation Trigger (21 CFR 807.87(l) & 82 FR 26807): The 21st Century Cures Act required FDA to publish the reusable device types for which a 510(k) must include validated reprocessing instructions and validation data. FDA published that list as a notice, not as a new cycle-count rule: 82 FR 26807, effective August 8, 2017. Current 21 CFR 807.87(l) incorporates the notice by reference. A 510(k) for a device identified in Table 1 or Table 2, or for an arthroscope, laparoscopic instrument, electrosurgical instrument, or respective accessory that contains a design feature identified in Table 2, must include instructions for use that have been validated and validation data regarding cleaning, disinfection, and sterilization. Table 2 is soil-retaining geometry: lumens (including flexible, multiple, bifurcated, ridged, sharp-angled, or brush-inaccessible lumens), hinges, depressions, gapped or overlapping joints, interior channels, sleeves around rods, blades, activators, or inserters, shafts within lumens, ridges, articulations, grooves, and similar features that can entrap soil. The notice says that if those validated instructions and reprocessing validation data are inadequate, FDA will find the device not substantially equivalent. That is a submission-content duty for the listed devices. It does not prescribe how many cycles to run, and it is separate from the nonbinding labeling recommendations in the 2015 guidance. How weak reprocessing evidence appears in review is covered in our analysis of FDA 510(k) deficiency and rejection patterns.

• U.S. Administrative Guidance Policy (FDA 2015 Guidance, Section VI.L): In its landmark guidance Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling (Docket FDA-2011-D-0293, issued March 17, 2015; Appendix E updated June 9, 2017) recommends, in Criterion 5, Section VI.L (Reuse Life), two labeling routes. The labeling should either inform the user how many times the device can be reused, based on testing, or provide a mechanism or method to ascertain whether the device has exceeded its use life. For the second route, the labeling should identify a method to establish that the device is still within performance specifications and instructions for appropriate disposal of devices that fail. If reuse life is limited to a specific number of use or reprocessing cycles, the labeling should also describe a specific tracking method for that count. The guidance says it may be appropriate to remind users that the stated number depends on full compliance with the directions for use. Those sentences use 'should.' They are not a statutory cycle limit. The separate statement that the number of simulated-use cycles should be scientifically justified is in the cleaning-validation discussion at Section VIII.A.1.c, not in VI.L.

The Reprocessing Claim-to-Evidence Map

Choosing a fixed cycle count, an end-of-life indicator, or leaving service life unspecified changes the evidence you have to hold and the instruction a sterile processing department can actually follow. The matrix below maps each option to the regulatory text that governs it, the standard that operationalizes only part of the work, the evidence package, the facility burden, and the commercial assumption that does not substitute for that evidence.

To operationalize these routes, manufacturers rely on two primary international consensus standards: ISO 17664-1:2021 and ANSI/AAMI ST98:2022. Understanding the precise boundaries of each standard prevents severe regulatory missteps.

ISO 17664-1 Disclosure Mandates

Recognized by the FDA under Recognition Number 14-578 (List 058), ISO 17664-1:2021 specifies the information manufacturers must provide for processing critical and semi-critical medical devices. Rather than prescribing a lifecycle limit, ISO 17664-1 imposes three vital documentation requirements:

• Clause 4.2 (Validation of Processing Procedures): The manufacturer must hold objective evidence that validation of the processing procedures identified in the processing information was undertaken. That record shows the stated cleaning, disinfection, and sterilization processes were validated. It is not, by itself, a number of allowable reuses. For how to structure those processing instructions, see our ISO 17664 reprocessing validation guide and our framework for audit-ready IFU reprocessing instructions.

• Clause 6.3.1 (Degradation Disclosures): If processing in accordance with the manufacturer's instructions is known to cause degradation that might limit service life, the manufacturer shall provide that information on limitations and restrictions. The clause's examples are effects on functionality, biocompatibility, or suitability for effective processing. The clause does not add electrical performance as a mandatory endpoint, and it does not set a cycle number.

• Clause 6.3.2 (Service Life Limitations): If service life is limited by the number of processing cycles or by some other end-of-life indicator, that information shall also be provided. This is the disclosure duty that lines up with a fixed count or with an indicator. It is not a permission to leave both out.

The ST98 Scope Boundary: Cleaning Efficacy vs. Lifecycle Limits

A frequent deficiency in 510(k) and technical documentation reviews arises when manufacturers attempt to justify their device's overall reuse life simply by citing compliance with ANSI/AAMI ST98:2022 (FDA Recognition 14-583, List 059, entered December 19, 2022). ST98 sets requirements for developing and validating a cleaning process for devices that must be cleaned before each use, and it replaced AAMI TIR30 for that scope. Its subject is cleaning-process validation: test soil, simulated use, extraction, and the acceptance criteria the protocol sets for residues. Some cleaning studies, including the 2025 end-of-life study discussed below, apply protein and total-organic-carbon figures they attribute to ST98 (6.4 µg/cm² protein and 12 µg/cm² TOC). Those figures are cleaning endpoints. They do not establish how many times a device may be reprocessed.

ST98 does not validate a reuse-life number. A washer-disinfector cycle that meets a cleaning endpoint does not show that jaws, optics, polymers, insulation, or markings still meet their specifications after the number of cycles on the label. Soil, residue endpoints, and worst-case device selection for cleaning are covered in our companion guide on cleaning validation soil residue and worst-case testing.

Building the Aging Protocol: Connecting Simulated Cycles to Claims

A defensible reuse claim separates three uses of repeated cycling. Mixing them is how a cleaning study gets filed as if it were a use-life study.

1. Soil-accumulation cycles for process validation: Simulated-use conditioning for cleaning, disinfection, and sterilization validation. FDA's Section VIII.A.1.c says validation studies should incorporate multiple full use cycles and should be designed to assess accumulation of soil over time, and that the number of simulated-use cycles should be scientifically justified. These cycles soil the device the way it is used, including repeated articulations where that is the intended use. They answer whether residue builds up. They do not, by themselves, justify a labeled maximum such as 50 or 100.

2. Aging to the labeled end state: End-of-life aging to the state named on the label. If the claim is a count, representative devices are processed through that count with the soil, cleaning, and sterilization parameters the instructions actually specify. If the claim is an indicator, devices are processed far enough to show when corrosion, pitting, discoloration, cracked seals, or loss of function appears, and to show that the inspection method detects it. The count used for soil-accumulation studies and the count used for this aging step are different design choices and should be justified separately.

3. Checks at that end state: Verification at that aged state. Function, biological safety, cleanability, and the terminal microbicidal process are checked on devices that have reached the claimed end state. Passing those checks at cycle zero, or after only the soil-accumulation cycles, does not answer a label that still places the device on the market at cycle N.

flowchart TD
    A["Devices at the start of the claimed life"] --> B["Separate the question being asked"]
    B --> C["Soil-accumulation cycles for cleaning and microbicidal validation"]
    B --> D["Aging to the labeled count or to the inspection endpoint"]
    C --> E["Washer-disinfector and terminal process named in the IFU"]
    D --> E
    E --> F["Repeat intended articulations where use pushes soil into the device"]
    F --> G{"Claimed end state reached?"}
    G -- "Not yet" --> C
    G -- "Yes" --> H["Evaluation at that state"]
    H --> I["Visual criteria: corrosion, pitting, discoloration, cracked seals"]
    H --> J["Function still inside the specifications you claim"]
    H --> K["Biological evaluation at the maximum validated processing cycles"]
    H --> L["Cleaning and terminal process still meet their endpoints"]
    I --> M["Label: tested count with a tracking method, or an end-of-life method"]
    J --> M
    K --> M
    L --> M

Debunking the 'Six-Cycle FDA Requirement' Myth

A recurring claim in laboratory marketing is that FDA requires exactly six repeated reprocessing cycles. The published guidance does not. Section VIII.A.1.c says validation studies should incorporate multiple full use cycles, should be designed to assess accumulation of soil over time, and that the number of simulated-use cycles should be scientifically justified. One contract laboratory has described a single 510(k) deficiency in which a reviewer asked for six repeated soiling, cleaning, and disinfection cycles after a disinfection validation that did not repeat cycles. That is one anonymized account from a laboratory that sells the testing. It is not a rule.

In reality, six is not a published FDA requirement. Section VI.L does not contain that sentence. Section VIII.A.1.c does, and it uses 'should be scientifically justified,' not a fixed integer. In the March 24, 2015 FDA webinar on the guidance, a questioner described a historical practice of about six to ten simulated-use cycles and asked whether sponsors must now calculate a statistically larger number tied to the whole service life. FDA staff answered that the number depends on the complexity and details of the device and should be discussed with the review division. Do not replace that answer with a house number. A simple instrument with no soil-retaining features is not automatically a six-cycle file, and a multi-lumen or elevator-channel device is not automatically a 10- or 20-cycle file. Justify the number from the features that can accumulate soil, document the rationale, and expect the review division to challenge it when the device is on the 82 FR 26807 list.

Reconciling U.S. and EU Reprocessing Parameters

If both the United States and the European Union are in the intended markets, the aging protocol has to cover the parameters the instructions will actually name. Running two complete cohorts is sometimes necessary. A single hybrid is justified only when you can show it is at least as stressful, for the properties you are claiming, as each market's specified cycle. The 2025 Patel and Olsen study, discussed below, is a concrete example of that choice and of its limit.

• Steam Sterilization Time and Temperature: The Patel and Olsen paper states that European prevacuum steam cycles for critical and semi-critical devices typically run at 134°C for 3 minutes, and U.S. prevacuum cycles at 132°C for 4 minutes. Their laboratory hybrid was one cycle at 134°C for 4 minutes, with three preconditioning pulses and 30 minutes of drying, not a sequence that ran both regional cycles. That hybrid envelopes the higher temperature and the longer exposure they cited. It does not envelope extended prion-inactivation holds, every national cycle, or a parameter your IFU does not claim. Steam-cycle design itself is covered in our guide on ISO 17665 steam sterilization validation.

• Washer-Disinfector Thermal Disinfection and Chemistry: Washer chemistry and A0 are part of the same problem. The Patel and Olsen cycle used an alkaline detergent at 1.25 oz/gal in a 60°C wash, followed by a neutralizer, then a pure-water rinse. That is one laboratory's worst-case wash, not a census of U.S. or European hospitals. ISO 15883 uses A0 to describe thermal disinfection, and 600 is a commonly applied minimum for instrument disinfection, with higher values used when the instructions require them. If your EU instructions specify an alkaline wash or a higher A0 than the U.S. instructions, material aging should include that harsher specified condition or a documented reason why it is not worse for the property under test. Do not cite a hospital-practice average you have not measured. Washer validation detail is in our overview of washer-disinfector thermal disinfection A0 validation.

Product Family Bracketing and Worst-Case Selection

FDA's 2015 guidance, Section VII, allows a product-family approach when design, materials, and other factors are similar enough that validation on the most difficult device to reprocess — the master device — covers devices that present an equivalent or lesser challenge. The features the guidance tells you to compare include lumen length and diameter, materials, configuration, and texture relevant to the reprocessing challenge. The justification has to be documented. A change in design or materials that could affect sterilant penetration or potency can force a new validation. That master-device rule is about reprocessing challenge. It is not a waiver of the use-life claim for every other catalog number if a shorter lumen still uses a different polymer, coating, or marking.

• Internal Lumen Dimensions: The longest, narrowest lumen is the usual cleaning and steam-penetration challenge. State the lengths and diameters you compared. Do not assume the hardest device to clean is also the first device to lose jaw alignment, insulation, or marking readability.

• Mechanical Crevices and Articulations: Box locks, sliding channels, serrations, and shielded pivots are the features Table 2 and the cleaning guidance both treat as soil traps. They are also the places a use-life inspection has to be able to see, which is why VI.L calls out hard-to-see areas separately from the cleaning endpoint.

• Dissimilar Material Junctions: If one family member adds a polymer, coating, adhesive, or direct-part mark that the master metal device does not have, that member is not covered by a metal-only aging run. ISO 17664-1 asks you to disclose processing-driven degradation that can limit service life, including effects on functionality, biocompatibility, or suitability for processing. A different material can change which of those fails first.

Evidence from 100-Cycle Studies: Residues Versus Degradation

Patel and Olsen, writing in Biomedical Instrumentation & Technology (2025; authors at Nelson Laboratories), ran a 100-cycle protocol to ask whether residues accumulate, not whether every reusable device can be labeled for 100 uses. The paper is useful because it separates those questions, and it is limited because the test articles were coupons and hemostats.

The Patel & Olsen (2025) Study: 100 Cycles Across Seven Materials

The test articles were seven coupon materials — aluminum, anodized titanium, nitinol, Delrin, PEEK, stainless steel, and a titanium alloy — plus hemostats. The paper reports 35 coupons (five of each material) and 50 hemostats. Each cycle was soiling with a defibrinated blood soil (sheep blood, egg yolk, and hog mucin), drying at ambient temperature, a utility-water prerinse, an automated washer-disinfector cycle with alkaline detergent, and one prevacuum steam cycle at 134°C for 4 minutes. Five hemostats were extracted every 10 cycles for cytotoxicity, protein, and total organic carbon. Coupons were extracted only after 100 cycles, because the coupon inventory was limited. Cytotoxicity used the MTT assay on L929 cells under ISO 10993-5, with the paper's acceptance criterion of greater than 70 percent cell viability. Protein used a micro-BCA assay and TOC a wet-oxidation method. The authors set acceptance criteria they attribute to ANSI/AAMI ST98:2022 at 6.4 µg/cm² protein and 12 µg/cm² TOC. The paper cites ISO 10993-1 as a 2021 edition, section 4.8. There is no 2021 edition; the clause 4.8 wording belongs to the 2018 fifth edition. Treat that citation as the authors' pointer to the reusable-device duty, not as the edition year.

Hemostats showed no pattern of residual accumulation for cytotoxicity, protein, or TOC across the 100 cycles relative to those acceptance criteria. Coupons after 100 cycles likewise showed no substantial accumulation of residuals, and protein and TOC results were below the acceptance criteria. MTT results were read as no cytotoxic residuals under the paper's viability criterion. That is not a finding of zero residue, and it is not an MEM-elution grade of 0. The authors' conclusion is narrower than a universal clean-forever claim: the results do not support the assumption that processing residues are likely to accumulate to harmful levels over 100 cycles for all devices, compared with the acceptance criteria they used.

What the inspections actually recorded was limited cosmetic change, and the study did not measure clamping force, spring recoil, or ratchet engagement:

• Surface Discoloration and Tarnishing: Discoloration and tarnishing on some aluminum, Delrin, PEEK, and anodized-titanium coupons. The paper calls this minor surface damage and says it did not considerably influence the residue results. It does not report oxide-layer growth or caustic micro-pitting as measured mechanisms.

• Superficial Corrosion at Friction Points: Some discoloration and rusting on the hemostats. The paper says the amounts were not substantial enough to affect the residue results. It does not locate that rust at box locks or ratchet serrations, and it does not report a mechanical specification check.

• Functional Preservation: The authors still tell manufacturers to prioritize material degradation and functionality in the instructions, rather than treating the allowable cycle count as the only end-of-life question. That recommendation is broader than the measurements in the study. Use it as a reason to write inspection criteria, not as evidence that function was unchanged.

The same paper states the limit that matters for a complex device: the study did not account for complex or difficult-to-clean features, because coupons were used, and further work is needed on surgical devices with those features. 'Performance at cycle 0 was equivalent to cycle 100' in the authors' later comments refers to the residue and cytotoxicity results, not to a mechanical endurance test. Do not extend the no-accumulation finding to endoscopes, lumened shavers, or elevator channels.

What the Endoscope Cost Paper Does and Does Not Show

Hoffman and Cool, Clinical Endoscopy 2024 (doi 10.5946/ce.2023.164; received 2023), estimate the time and cost of moving facilities to ANSI/AAMI ST91:2021. Both authors are with Ambu USA, which sells single-use endoscopes, and the paper discloses that employment. In the discussion of in-house sterilization they write that a facility may still pay for repairs in as little as every eight reprocessing cycles due to glue blistering and every 23 cycles due to insertion-tube cracking. Those intervals are cited from another study. They are not a multi-center count of bite damage, coiling damage, or bending-rubber perforations, and this article does not treat them as a field average.

The useful boundary is narrower. A residue study on coupons and hemostats does not tell you the reuse life of a flexible endoscope, and a sterilization-compatibility repair interval cited in a cost paper does not tell you that clinical handling fails the device on a fixed schedule. For a device whose known damage modes are glue, insertion-tube cracking, leaks, or loss of angulation, FDA's VI.L example is the inspection route: a method, such as leak testing, that shows whether the device is still within performance specifications before the next use. A high fixed count is the harder claim, because you then also need a tracking method and evidence at that count. It is not inherently noncompliant. It is noncompliant when the number is copied and the file never reaches it.

IFU Labeling, Facility Tracking, and the Single-Use Boundary

Ambiguous instructions are a common review problem, but this article does not treat any particular phrase as a statistic of notified-body findings. Write the instruction to the route you actually validated.

Drafting Actionable IFU Instructions

If you claim a fixed count under the first VI.L route, the guidance asks for two labeling elements. Neither is phrased as a statutory 'must' inside VI.L:

1. Specify an Actionable Tracking Mechanism: The labeling should describe a specific tracking method for the number of reuse cycles. FDA does not prescribe laser tally marks, RFID, or a log sheet. Those can be examples if the facility can actually perform them and if the method survives reprocessing. A sentence that only says 'discard after 50 cycles,' with no way to know the count, does not meet the recommendation.

2. Include the Full-Compliance Contingency Statement: It may be appropriate to remind the user that the stated number depends on full compliance with the directions for use. That is the guidance's wording. An example, not a required sentence, is: 'This instrument is validated for up to the stated number of reprocessing cycles only when processed as specified in these instructions. The count should be tracked by the method named here.'

For the second VI.L route, and for the examples in MDR GSPR 23.4(n), the instructions should identify when the device should no longer be reused. FDA's published examples are unacceptable deterioration such as corrosion, discoloration, pitting, and cracked seals, plus a method for areas that are hard to see, especially lumens, with leak testing given as the example. Millimeter limits, jaw-gap tolerances, gauze-cut tests, and pressure-drop numbers are device-specific acceptance criteria. They belong in your protocol if you validated them. They are not a universal list, and copying them from an unrelated instrument is the same error as copying a cycle count.

• Visual Surface Criteria: Use the deterioration modes you can actually show a processor: corrosion, discoloration, pitting, cracked seals, damaged coatings, or illegible markings. If you add a numeric size limit, it has to come from your own inspection validation, not from a generic millimeter.

• Mechanical Function Criteria: State the function the user can check before reuse, in the same terms as the performance specification: jaw alignment, cutting, ratchet hold, angulation, or insulation, as applicable. A numeric limit or a bench demo is acceptable only when that check is the one you validated for this device.

• Hard-to-see areas: For lumens and other hard-to-see areas, VI.L's example is leak testing. Specify the method the user performs. Do not import a pressure-drop number from an unrelated device.

Direct Part Marking and UDI Durability Across Reprocessing

MDR Annex VI, Part C, Section 4.10 requires devices that are reusable to bear a UDI carrier on the device itself. For reusable devices that require cleaning, disinfection, sterilisation, or refurbishing between patient uses, that carrier shall be permanent and readable after each process performed to make the device ready for the subsequent use, throughout the intended lifetime of the device. Section 4.11 adds that the carrier shall be readable during normal use and throughout the intended lifetime. If the marking is no longer readable before the lifetime you claim, the UDI requirement is not met for that claimed lifetime. The regulation does not automatically rewrite the lifetime to 'one cycle before the marking failed.' You shorten the intended lifetime, or you change the marking, and you show the carrier still meets 4.10 for the lifetime you then claim.

The Legal Boundary: Reusable Devices vs. Reprocessed SUDs

Original reusable devices and reprocessed single-use devices are different legal objects. Under FD&C Act section 510(o), a reprocessor of a class I or class II single-use device that is not exempt must submit a 510(k) that includes testing and validation data evaluated for a specified maximum number of times the device is reprocessed: cleaning, disinfection, sterilization if required, and functional performance, including the rationale for that maximum. FDA's page on reprocessed single-use devices states the point directly: the data have to show the reprocessed device is substantially equivalent to a predicate after the maximum number of times the reprocessor intends to reprocess it. Class III reprocessed single-use devices follow the premarket approval path, with validation data for the same maximum. There is no indicator-only alternative in that statute. The reusable-device choice between a count and an end-of-life method does not transfer to the reprocessor.

On the EU side, MDR Annex I GSPR 23.2(o) is a label requirement for a single-use device that has been reprocessed: an indication of that fact, the number of reprocessing cycles already performed, and any limitation as regards the number of reprocessing cycles. Article 17 is the reprocessing regime for single-use devices and is outside the reusable-device decision this article maps. The contrast, and only the contrast, is that the reprocessor's U.S. file is count-based, while the original reusable device may use either VI.L route if the evidence matches the sentence on the label. The single-use regime is summarized in our single-use device reprocessing regulatory framework.

The 2025–2026 ISO 10993-1 Transition and Roadmap to 2029

A pivotal regulatory evolution occurring across 2025 and 2026 centers on ISO 10993-1. The reusable-device duty is older than the 2025 edition. ISO 10993-1:2018 clause 4.8, as quoted by secondary carriers of the paywalled standard, says biological safety of a re-usable device shall be evaluated for the maximum number of validated processing cycles. The sixth edition, published November 2025, keeps a lifecycle expectation. Published summaries describe a duty to set and validate the claimed number of processing cycles, or to justify biological risk controls when no maximum is specified. Do not cite 'ISO 10993-1:2025 clause 4.8' until the purchased text is checked. Clause numbers moved.

What Changed in the Sixth Edition

The 2018 clause, not a new 2025 clause number, is the text secondary sources quote as: for re-usable medical devices, biological safety shall be evaluated for the maximum number of validated processing cycles. The sixth edition's lifecycle wording should be read in the purchased standard before it is quoted. Repeated processing can change surfaces and residues, which is why the evaluation follows the claimed processing cycles. It is not accurate to say the 2025 edition newly invented that duty, or that every auditor now rejects a cycle-zero sample regardless of justification. The 2018 clause already pointed biological evaluation at the maximum validated processing cycles. The edition change, FDA's partial recognition, and the transition date are the 2025–2026 facts that change the file you can cite. Detail on the edition itself is in our analysis of the ISO 10993-1:2025 biological evaluation update.

FDA Partial Recognition and the 2029 Submission Window

On May 25, 2026, the FDA formally recognized the sixth edition of ISO 10993-1 (Recognition Number 2-313, List 066). However, the agency granted partial recognition. The extent of recognition is partial. The entry says the following parts are not recognized: the phrase 'consumer products' in clause 6.5.11.3, and clause 6.9, biological risk estimation. A separate note says the additional genotoxicity evaluation requirements in Tables 2, 3, and 4 and clause 6.5.7 may not align with FDA's biocompatibility guidance for all prolonged-contact devices, and it tells sponsors to contact the review office before relying on those requirements. That note is not the list of unrecognized clauses. A declaration of conformity has to account for the excluded text. It cannot treat the sixth edition as fully recognized.

The same recognition entry states the transition. Recognition of ISO 10993-1 fifth edition 2018-08 (recognition 2-258) is superseded by recognition of the sixth edition (recognition 2-313). FDA will accept declarations of conformity, in support of premarket submissions, to recognition 2-258 until July 1, 2029. After that date, declarations of conformity to the 2018 edition will not be accepted. The date governs which edition you may declare. It does not, by itself, require every device already on the market to be retested before July 2029. It does mean a reusable-device file that still cites only a cycle-zero biological evaluation is a weak answer to both the 2018 clause and the 2025 lifecycle text, whenever you next rely on a declaration of conformity.

Strategic Action Checklist for RA/QA Teams

For a reusable portfolio, the practical sequence is the claim first, then the evidence that matches it:

1. Audit Current IFU Claims: Review all active instructions for use across your reusable portfolio. Determine whether each product line claims a fixed cycle count, an end-of-life indicator, or remains silent. Eliminate any unsupported cycle numbers inherited from historic predicate devices.

2. Establish Worst-Case Aging Rationales: Document the master device the way Section VII describes it: lumen length and diameter, materials, configuration, and texture relevant to reprocessing, plus any polymer, coating, adhesive, or direct-part mark that could fail earlier than the metal master. A family bracket covers a lesser reprocessing challenge. It does not cover a different use-life failure mode you never tested.

3. Execute Dual-Market Aging Protocols: Age to the parameters the instructions name for each market. A single hybrid, such as the 134°C for 4 minutes cycle used by Patel and Olsen, is a justification only when it is at least as stressful as each claimed cycle for the property under test. It is not a default that satisfies every 510(k) and every EU technical file.

4. Test Biocompatibility and Markings at Cycle N: Put the biological evaluation on the maximum number of validated processing cycles you claim, and confirm the UDI carrier required by MDR Annex VI Part C Section 4.10 is still readable after each process throughout that intended lifetime. Record the clause number from the edition you actually declare.